PD-1 Inhibitor
Various Cancers
Phase 2/3Active
Key Facts
About Akeso
Akeso Inc. is a clinical-stage biopharmaceutical company headquartered in China, specializing in the research, development, and commercialization of innovative cancer immunotherapies. The company has built a robust pipeline of immune checkpoint inhibitors and bispecific antibodies, with several candidates in late-stage clinical trials. As a publicly traded company on the Hong Kong Stock Exchange, Akeso represents one of China's most promising biotech companies in the oncology space.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Phase 3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Tazverik (tazemetostat) | Eisai | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |
| Logic-gated Switch-DARPins | Molecular Partners | Preclinical |